Adult Height after Growth Hormone Treatment at Pubertal Onset in Short Adolescents Born Small for Gestational Age: Results from a Belgian Registry-Based Study
Table 2
Comparison of auxological data at start of GH treatment and at adult height between the PrePUB and PUB groups.
n
PrePUB group
PUB group
Significance
Males ()
Females ()
Males ()
Females ()
At start of GH treatment
Age (yr)
74
10.1 ± 3.0
10.0 ± 2.2
13.6 ± 1.3
11.3 ± 1.3
/
Height, SDS
74
−3.2 ± 0.6
−3.3 ± 0.7
Weight, SDS
74
−3.0 ± 1.1
−2.8 ± 1.1
BMI, SDS
73
−1.1 ± 1.1
−1.1 ± 1.2
At adult height
Age (yr)
74
18.4 ± 1.8
16.1 ± 1.4
18.7 ± 1.6
16.4 ± 1.7
/
Height, SDS
74
−2.1 ± 1.0
−2.5 ± 0.7
Weight, SDS
67
−1.6 ± 1.1
−1.6 ± 1.0
BMI, SDS
67
−0.6 ± 0.9
−0.3 ± 1.0
Height SDS corr. for midparental height
67
−0.7 ± 1.1
−0.5 ± 1.0
Height (cm)
167.5 ± 7.7
153.4 ± 4.8
165.2 ± 4.9
150.8 ± 4.4
/
Adult height > −2 SDS
74
12/27 (44.4%)
13/47 (27.7%)
Adult height SDS > parent-specific lower limit of height
67
16/24 (66.7%)
30/43 (69.8%)
Height gain, SDS
74
1.1 ± 0.7
0.8 ± 0.7
Daily GH dosage (μg/kg/day)
74
45.2 ± 8.5
41.8 ± 8.4
Duration GH therapy (yr)
74
6.8 ± 2.5
5.1 ± 1.3
4.1 ± 1.1
4.1 ± 1.2
/
In males from the PrePUB group versus the PUB group/in females from the PrePUB group versus the PUB group.
